You are now leaving myCME and connecting to our educational partner. myCME does not control content, practices, or other policies of the site you are entering.
Recurrent herpes simplex labialis (HSL) is a common condition usually caused by reactivation of herpes simplex virus-1, with lifelong potential for reactivation leading to disease recurrence. As this case highlights, in the immunocompromised host, HSL tends to be more severe and debilitating. This is the second of 3 in-depth case studies on herpes labialis, focusing on different patient populations, degree of severity, inter-related symptoms, differential diagnosis, and different treatment options.
Upon completion of this activity, participants should be better able to:
Stephen K. Tyring, MD, PhD, MBA, has nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. [Medical Education Resources, Meda Pharmaceuticals, Inc., and Haymarket Medical do not recommend the use of any agent outside of the labeled indications].
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Medical Education Resources, Meda Pharmaceuticals, Inc., and Haymarket Medical. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This program is sponsored by Medical Education Resources.
If you have any questions relating to the accreditation of this activity, please contact Tami Good at firstname.lastname@example.org.
This program is supported by an educational grant from Meda Pharmaceuticals, Inc.
CE for Pharmacists
Medical Education Resources is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Medical Education Resources designates this continuing education activity for .50 contact hours (0.005 CEUs) of the Accreditation Council for Pharmacy Education. Universal Program Number 816-9999-10-017-H01-P. This activity is certified as knowledge-based CPE.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medical Education Resources and Haymarket Medical Education.
Medical Education Resources is accredited by the ACCME to provide continuing medical education for physicians. Medical Education Resources designates this educational activity for a maximum of .50 AMA PRA category 1 creditTM. Physicians should claim credit commensurate with the extent of their participation in the activity.
To obtain credit, a score of 70% or better is required. This CME is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the posttest survey, and have received your digital copy of your credit certificate. Your online certificate will be saved on myCME.com within your Profile/Exam History, which you can then access at any time.